Core Viewpoint - ImmunityBio, Inc. has announced a public offering of 33,333,334 shares of common stock at a price of $3.00 per share, aiming to raise approximately $100 million in gross proceeds [1][3]. Group 1: Offering Details - The underwriters have a 30-day option to purchase an additional 5,000,000 shares at the public offering price [1]. - The offering is expected to close on or about December 12, 2024, subject to customary closing conditions [1]. - Jefferies and Piper Sandler are acting as joint book-running managers for the offering, with BTIG and H.C. Wainwright & Co. as co-lead managers [2]. Group 2: Use of Proceeds - The net proceeds from the offering will be used to advance the commercialization of ANKTIVA® for treating BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) and to fund trials in BCG-naïve NMIBC and non-small cell lung cancer (NSCLC) [3]. - Additional uses include further research and development, working capital needs, and other general corporate purposes [3]. Group 3: Company Overview - ImmunityBio is a biotechnology company focused on developing immunotherapies that enhance the natural immune system to combat cancers and infectious diseases [5]. - ANKTIVA® is the first FDA-approved immunotherapy for non-muscle invasive bladder cancer CIS, designed to activate natural killer cells and T cells for a prolonged immune response [5].

Core Insights - ImmunityBio, Inc. and nCartes, Inc. have entered a collaboration to automate and streamline the data fulfillment process for clinical trials, aiming to enhance efficiency and reduce costs for trial investigators [1][2][3] Group 1: Collaboration Details - The collaboration will utilize digital information from electronic medical record (EMR) systems to directly populate Electronic Data Capture (EDC) systems, replacing the traditional manual data entry process [2][3] - This new approach is expected to reduce delays in clinical trials, improve data quality by minimizing entry errors, and lower costs associated with source data verification [3][4] Group 2: Company Profiles - ImmunityBio is a vertically-integrated biotechnology company focused on developing therapies and vaccines that enhance the immune system to combat cancers and infectious diseases, with a notable product being ANKTIVA®, the first FDA-approved immunotherapy for non-muscle invasive bladder cancer [5] - nCartes is a cloud software platform provider that enables clinical research sponsors to automate data capture for clinical trials and other applications, leveraging electronic health systems [4][5]

Core Viewpoint - ImmunityBio (IBRX) shares have increased by 41.1% in the past four weeks, closing at $5.01, with a mean price target of $14.25 suggesting a potential upside of 184.4% [1] Price Targets - The average price target consists of three estimates ranging from a low of $4.75 to a high of $30, with a standard deviation of $13.74, indicating variability among analysts [2] - The lowest estimate suggests a decline of 5.2%, while the highest indicates a potential upside of 498.8% [2] Analyst Sentiment - Analysts show strong agreement on IBRX's ability to report better earnings than previously predicted, which supports the potential for stock upside [4] - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 2.9%, with one estimate moving higher and no negative revisions [10] Zacks Rank - IBRX holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, indicating a strong potential upside [11] Earnings Estimate Revisions - There is a strong correlation between trends in earnings estimate revisions and near-term stock price movements, suggesting that the positive revisions could lead to stock price increases [9]

Group 1 - Schubert Jonckheer & Kolbe LLP is investigating potential legal claims related to ImmunityBio, Inc.'s unsuccessful efforts to secure regulatory approval for its product Anktiva, which is intended for bladder cancer treatment [1] - A class action complaint has been filed against ImmunityBio, alleging that the company misled investors about the prospects of obtaining FDA approval for Anktiva by concealing issues related to recordkeeping, quality control, and sanitation at its contract manufacturer [2] - Following the revelation of these issues in May 2023, ImmunityBio's stock experienced a significant decline of 55% [2] Group 2 - The Schubert firm is looking into potential wrongdoing by ImmunityBio's officers and directors in connection with the allegations made in the class action complaint [3] - Current shareholders of ImmunityBio are encouraged to seek additional information regarding their legal rights [3]

ImmunityBio (IBRX) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to loss of $0.19 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 22.22%. A quarter ago, it was expected that this immunotherapy company would post a loss of $0.17 per share when it actually produced a loss of $0.20, delivering a surprise of -17.65%.Over the last four quarters, the company h ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37507 _____________________________________ IMMUNITYBIO, INC. (Exact name of registrant as specified in i ...

EXHIBIT 99.1 ImmunityBio Reports Third-Quarter 2024 Financial Results CULVER CITY, Calif.—Nov. 12, 2024—ImmunityBio, Inc. (NASDAQ: IBRX) today announced its financial results for the thirdquarter ended September 30, 2024. ® • ANKTIVA received a J-code (HCPCS Level II Code) in October 2024, effective January 1, 2025. • ANKTIVA (FDA-approved and commercially available in the U.S. since May 2024) is now widely accessible to patients through commercial and government insurance programs (VA, DoD, Medicare). Immu ...

NEW YORK, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against ImmunityBio, Inc. (NASDAQ: IBRX) on behalf of long-term stockholders following a class action complaint that was filed against ImmunityBio on June 30, 2023 with a Class Period from May 23, 2022 to May 10, 2023. Our investigation concerns whether the board of directors of ImmunityBio have breached their fiduciary duties to the company. Immunit ...

ImmunityBio (IBRX) shares soared 26.4% in the last trading session to close at $5.32. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 8% gain over the past four weeks.Last week, the company announced the dosing of the first patient in a phase I study evaluating its CAR-NK cell therapy, CD19 t-haNK, for treating relapsed B-cell non-Hodgkin lymphoma. This might have driven the share price rally.This immunotherapy company is expecte ...

EF Hutton has initiated coverage on ImmunityBio Inc. IBRX, a vertically integrated biotechnology company developing therapies and vaccines to bolster the natural immune system for cancers and infectious diseases. In April this year, the FDA approved ImmunityBio's Anktiva (N-803, or nogapendekin alfa inbakicept-pmln) plus Bacillus Calmette-Guérin (BCG) for BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The analyst writes, "Anktiva has the potenti ...